AZ has another setback with Truqap after failed TNBC trial June 18, 2024 AutoBot News 0 AstraZeneca’s first-in-class pan-AKT inhibitor Truqap was unable to improve overall survival (OS) in a phase 3 trial in triple-negative breast cancer (TNBC), denting the prospects of the new drug.